EditorialCancer Lett2026
Targeting the stromal-immune barrier: A novel strategy to overcome resistance to CLDN18.2/CD3 bispecific T-cell engager therapy in pancreatic cancer.
- Journal
- Cancer Lett
- Published
- 8 January 2026
- Citations
- 0
- Type
- Editorial
These are bibliographic fields. A study card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try